Jubilant Pharmova's future bio prospects are strong, driven by strategic investments in its core businesses: Radiopharma with its growing Ruby-Fill® and PET radiopharmacies, the expanding CDMO Sterile Injectables sector supported by strong customer traction in Spokane and the integration of a new French R&D facility, the CRDMO business focusing on drug discovery and APIs, and the continued progress in the proprietary novel drugs business with its ongoing clinical trials for JBI-802 and JBI-778. The company is also seeing increased demand for its Allergy Immunotherapy products and foresees growth and profitability improvements in its Generics segment, solidifying its diversified growth strategy.